Hereditary Cancer Testing Market By Cancer Type (Breast & Ovarian Cancer, Colorectal Cancer, Prostate Cancer, Pancreatic Cancer, Endocrine & Neuroendocrine Tumors, Renal Cancer, Others), By Test Type (Single-Gene Testing, Syndrome-Specific Panels, Comprehensive Multigene Panels, Whole-Exome Sequencing (WES), Whole-Genome Sequencing (WGS)), By Sample Type (Blood, Buccal Swab, Dried Blood Spot (DBS), Others), By Technology (Next-Generation Sequencing (NGS), Sanger Sequencing, Multiplex Ligation-dependent Probe Amplification, Quantitative PCR, RNA Sequencing, Long-Read Sequencing), By Distribution Channel (Physician-Ordered Testing, Institutional Programs, Insurer-Sponsored Programs, Direct-to-Consumer (DTC) Testing, Partner-Led Sales), and By End User (Hospitals & Clinics, Reference Laboratories, Oncology & Specialty Clinics, Genetic Counseling Centers & Networks, Online Genetic Testing Providers, Others), Global Market Size, Segmental Analysis, Regional Overview, Company Share Analysis, Leading Company Profiles and Market Forecast, 2025 – 2035.

---

What trends will shape the Hereditary Cancer Testing Market in the coming years?

The Hereditary Cancer Testing Market accounted for USD 7.89 Billion in 2024 and USD 8.59 Billion in 2025 is expected to reach USD 20.18 Billion by 2035, growing at a CAGR of around 8.91% between 2025 and 2035. The Hereditary Cancer Testing Market will witness growth on account of increasing adoption of multigene panels and NGS, growing awareness of hereditary cancer risk, and increasing demand for personalized medicine. An expansion of direct-to-consumer testing and genetic services will improve accessibility. Advances in the integration of AI and bioinformatics will help to improve variant interpretation accuracy and timescales. Interlaboratory and interhospital networks will be more developed. Growth in preventive healthcare and population screening programs. Rising payer coverage and reimbursement will see further positive impact on market adoption. Regulatory harmonization and standardization will increase confidence in the worldwide market.

What do industry experts say about the Hereditary Cancer Testing market trends?

"We aim to implement genetic testing for every newborn, focusing on 450 clinically actionable conditions to enable pre-symptomatic intervention."

• Katherine Stueland, CEO of GeneDx.

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Hereditary Cancer Testing market?

What factors accelerate the adoption of multigene panels in hereditary cancer risk assessment?

Numerous reasons are driving the faster adoption of multigene panels in the hereditary cancer testing market. These are panels that can be analyzed concurrently with several genes that have been linked to hereditary cancers in a more comprehensive approach than the single-gene tests. With the development of Next-Generation Sequencing (NGS), genetic testing has become more affordable and faster, becoming more accessible to most patients and medical staff. Multigene panel testing has been suggested by clinical guidelines as having a positive effect on the treatment choices and preventive measures of individuals with diagnosed cancers, including triple-negative breast cancer, ovarian cancer, and early-onset colorectal cancer.

With better insurance coverage, more medically necessary tests will be reimbursed, which will be adopted. By increasing the availability of genetic counseling services, patients are able to interpret test results and make wise choices about their health. Genetic testing has been emphasized in public health campaigns and awareness programs as a way of early detection of the risk of cancer. The Centers for Disease Control and Prevention (CDC) notes that, with multigene panel testing, multiple genes such as BRCA1 and BRCA2 can be detected at the same time to help in a thorough assessment of the risk. Oncology is becoming a part of everyday healthcare practice in institutions where these panels are being implemented. Together, these reasons are leading to the widespread adoption and use of multigene panels in inherited cancer risk assessment.

How does growing awareness of personalized medicine increase hereditary cancer testing demand?

The hereditary cancer testing market has been experiencing rising demand owing to the growing awareness of personalized medicine. Personalized medicine focuses treatments on the unique genetic characteristics of an individual, increasing their effectiveness in treating and reducing their adverse effects. With the advantages of the treatment categories, which are based on the principles of genetic information and the recognition of them by patients and healthcare professionals, the topic of genetic testing as a method of determining risks of hereditary cancer is gaining more and more interest. With the help of this approach, it is possible to identify the problem at an early stage and introduce individual preventive measures, enhancing the treatment results and the quality of services.

According to the National Cancer Institute, it is estimated that 50% of all forms of cancer are caused by genetic changes that are inherited, and it is due to this that genetic testing is important to people who are at risk. Genetic testing is currently clinically recommended to help with treatment decisions in patients diagnosed with certain types of cancers (e.g., triple-negative breast cancer or early-onset colorectal cancer). The increased insurance cover has enabled an increased number of people to have access to testing. Sensitization programs and health education have helped raise awareness on the impact of genetics on the risk of cancer even further. Genetic testing is finding its way into the mainstream oncology practice of hospitals and diagnostic labs. In sum, increasing awareness of personalized medicine is prompting the implementation and use of hereditary cancer testing within healthcare systems.

What high costs of hereditary cancer testing that limit accessibility across developing regions?

Access to the hereditary cancer testing market in developing countries is low because of the high cost of the testing. Next-generation sequencing (NGS) and multigene panels are not only expensive in terms of equipment and reagents but also in bioinformatic support. Low- and middle-income countries have little or no laboratory infrastructure and trained personnel, which exacerbates the operational costs even further. Importation expenses and supply chain problems of the special testing kits add to the costs. Genetic testing is rarely covered by insurance and, in most cases, prohibitively costly.

High costs discourage routine screenings and cut off chances to get early and preventive healthcare. Also, not all developing regions are aware of the risk of hereditary cancer and do not need testing, as it has clinical benefits. Remote populations may not have access to centralized testing facilities, and this would increase logistical costs. Genetic testing has limited government funding and subsidies, and limits its widespread adoption. Hence, expense has emerged as one of the primary obstacles to equal access to hereditary cancer testing worldwide.

How can direct-to-consumer genetic testing expand access to hereditary cancer screening?

Direct-to-consumer (DTC) genetic testing is enhancing the hereditary cancer testing market. Genetic information is more conveniently available and accessible, as these tests enable people to arrange genetic screenings without a prescription from a healthcare provider. The Centers for Disease Control and Prevention (CDC) notes that as of February 2020, 16% of adults in the United States had undergone one or more DTC genetic tests. Convenience, reduced price, and ease of sample collection are the reasons why at-home testing kits are so popular. DTC genetic tests can detect inherited cancer risks, such as the BRCA1 and BRCA2 genetic mutations associated with the increased risk of breast and ovarian cancer.

Despite the usefulness of these tests, they are not able to identify all possible variants, so confirmatory clinical testing is necessary to be accurate. Favorable outcomes also encourage people to refer to medical genetic counseling and further laboratory analysis. The use of DTC genetic testing is also supported by public awareness campaigns and coverage of its usage by the media. This will allow access to the populations that may not otherwise be able to obtain conventional clinical genetic testing. In general, DTC genetic testing is growing hereditary cancer screening by raising awareness, convenience, and active health care.

Which emerging markets present growth potential for hereditary cancer testing adoption?

The hereditary cancer testing market is witnessing major growth in emerging markets, with the highest shares being recorded across Asia. Due to widespread awareness of hereditary cancer risk factors, increasing attention to techniques for genetic testing, and the emphasis in the field of personalized medicine, India is also transitioning gradually towards adopting genetic testing. Australia benefits from China's large population, as there is huge market potential, as more and more people are asking why not seek an early detection and risk assessment for such cancers as breast, ovarian, and colorectal.

In China government support promotes genetic screening and embeds testing within oncology clinical pathways to advance wider access. The demand for hereditary cancer testing services is also on the rise in other countries of the Asia-Pacific region, such as Japan and South Korea. With better access to testing and services such as healthcare facilities, funding for research and genetic counseling, and technology, it is now promoting overall adoption. The relatively low cost of testing, coupled with increased insurance coverage, will further improve access. Genetic risk areas are making the headlines, leading to proactive health management through increased awareness and education. As such, emerging markets are increasingly being responsible for the global growth of hereditary cancer testing to facilitate early detection and individualized approaches towards treatment.

What are the key market segments in the Hereditary Cancer Testing industry?

Based on the cancer type, the Hereditary Cancer Testing Market is classified into Breast & Ovarian Cancer, Colorectal Cancer, Prostate Cancer, Pancreatic Cancer, Endocrine & Neuroendocrine Tumors, Renal Cancer, and Others. Breast and ovarian cancer have a large portion because there is a high prevalence of BRCA and a high awareness of BRCA mutations. Colorectal cancer is substantially reduced, thanks to screening initiatives and early detection initiatives for Lynch syndrome, among other factors. Prostate cancer testing is on the rise with the increased understanding of supportable genetic risk factors, including BRCA and HOXB13. This is due to poor prognosis and late diagnosis, and we are seeing growth in demand for pancreatic cancer testing.

Endocrine & Neuroendocrine Tumors added for the purposes of covering hereditary syndromes like RET and VHL mutations; renal cancer testing can help to detect genetic precursors. This section discusses melanoma, gastric, pediatric, and rare hereditary cancers. The classifications help the Gambling Disorder Care Team effectively target preventative care, early intervention, and customized treatment strategies for affected gamblers and the healthcare providers who are treating them.

Based on the technology, the Hereditary Cancer Testing Market is classified into Next-Generation Sequencing (NGS), Sanger Sequencing, Multiplex Ligation-dependent Probe Amplification, Quantitative PCR, RNA Sequencing, and Long-Read Sequencing. Next-Generation Sequencing (NGS) is the method of choice because of its high throughput and multiparametric capacity. Sanger sequencing continues to play an important role in confirming and validating variants.

Multiplex Ligation-dependent Probe Amplification (MLPA) is routinely used for fluorescence detection of large deletions or duplications. Quantitative PCR (qPCR) is a fast and specific method for the analysis of select gene mutations. RNA sequencing brings value in the form of discovering splicing alleles and expression-level changes. Long-read sequencing is emerging for structural variant detection and for repetitive regions. Together, these technologies improve accuracy, sensitivity, and the confidence of a pharmaceutical clinician in applying genetic tests to diagnose and treat hereditary cancers. Continuous innovations behind faster, cheaper, and more complete test solutions

Which regions are leading the Hereditary Cancer Testing market, and why?

The North American Hereditary Cancer Testing Market is leading due to the owing to the presence of sophisticated healthcare infrastructure and high acceptability of genetic testing. The United States has the best awareness of hereditary cancer risk and the extent of payer coverage. Canada makes contributions through government-funded screening programs and research programs. Demand for early detection and multigene panel testing is driven by increases in the prevalence of breast, ovarian, and colorectal cancers.

The newest technologies, such as NGS and RNA sequencing, are quickly translated into the bedside. Larger players, including Myriad Genetics and Invitae, expand their footprint across the region through strategic partnerships and innovative solutions. Financial and regulatory support for testing access has improved. Overall, North America continues to be a center for innovation, adoption, and market growth in hereditary cancer testing.

The Asia Pacific Hereditary Cancer Testing Market is growing due to the increasing healthcare awareness and improving medical infrastructure in the region, thus making it the fastest-growing market for hereditary cancer testing. Countries like China, India, and Japan are experiencing increasing demand for early detection of cancer and personalized medicine. Chronic incidence of breast, colorectal, and prostate cancers impacts the use of multigene panel testing.

Expansion of genetic counseling and a large number of private laboratories facilitates access. Stimulated by increases in government initiatives as well as health insurance coverage, preventive screening programs exist. Next-generation sequencing and RNA analysis technologies are accelerating through major cities. A number of joint ventures are increasing the footprint of the global testing company, coupled with local healthcare providers. In essence, Asia is well poised for significant market growth due to demographics, awareness, and technology adoption.

What does the competitive landscape of the Hereditary Cancer Testing market look like?

The Hereditary Cancer Testing Market is highly competitive, and its players are Myriad Genetics, Invitae, Fulgent Genetics, Guardant Health, and Exact Sciences, among others. These companies can offer complete hereditary cancer testing solutions using next-generation technology, such as Next-Generation Sequencing (NGS) and RNA Sequencing. Gaining market access and expanding test menus through the merging of Agami into wider target-market segments is a widely used strategy using strategic partnerships, mergers, and acquisitions. Prenetics will spin off Insighta in July 2025 with Professor Dennis Lo, a joint venture that is developing multi-cancer early detection liquid tests.

This market is projected to grow at a very high rate since the demand for personalized medicine as well as preventive medicine will grow. The highest share is in North America, and the fastest increasing region is Asia Pacific due to the awareness and improved health care facilities. Firms are also exploring new markets to exploit increasing screening programs. There is also a lot that governments and insurance coverage programs do to facilitate market penetration. Nonetheless, high testing and regulation costs still exist. Simply put, the landscape of competition is still influenced by innovation, strategic alliance, and technology integration.

Hereditary Cancer Testing Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Hereditary Cancer Testing industry?

• In July 2025, Prenetics and Prof. Dennis Lo established Insighta, aiming to develop a multi-cancer early detection blood test, Presight One, targeting over 10 cancers.
• In July 2025, TTAM Research Institute acquired 23andMe's assets following its bankruptcy, with Anne Wojcicki returning as CEO to lead the company.

Report Coverage:

By Cancer Type

• Breast & Ovarian Cancer
• Colorectal Cancer
• Prostate Cancer
• Pancreatic Cancer
• Endocrine & Neuroendocrine Tumors
• Renal Cancer
• Others

By Test Type

• Single-Gene Testing
• Syndrome-Specific Panels
• Comprehensive Multigene Panels
• Whole-Exome Sequencing (WES)
• Whole-Genome Sequencing (WGS)

By Sample Type

• Blood
• Buccal Swab
• Dried Blood Spot (DBS)
• Others

By Technology

• Next-Generation Sequencing (NGS)
• Sanger Sequencing
• Multiplex Ligation-dependent Probe Amplification
• Quantitative PCR
• RNA Sequencing
• Long-Read Sequencing

By Distribution Channel

• Physician-Ordered Testing
• Institutional Programs
• Insurer-Sponsored Programs
• Direct-to-Consumer (DTC) Testing
• Partner-Led Sales

By End User

• Hospitals & Clinics
• Reference Laboratories
• Oncology & Specialty Clinics
• Genetic Counseling Centers & Networks
• Online Genetic Testing Providers
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Myriad Genetics, Inc.
• Invitae Corporation
• Fulgent Genetics, Inc.
• Ambry Genetics Corporation
• GeneDx, Inc.
• Guardant Health, Inc.
• Qiagen N.V.
• SOPHiA GENETICS SA
• Prenetics Ltd.
• GRAIL, Inc.
• PathAI, Inc.
• Color Genomics, Inc.
• Blueprint Genetics Oy
• Counsyl, Inc.
• Natera, Inc.

Frequently Asked Questions (FAQs)